In our in vivo experiments, the iMSC secretome more effectively reduced the expression levels of key AD biomarkers (IL‐4, IL‐13, IL‐31, IL‐22, CCL17, CCL22, and TSLP) and other inflammatory cytokines (IFN‐γ, TNF‐α, IL‐1β, and IL‐6) in lesional skin compared to 0.03% Tacrolimus. The gene discussed is IL13; the disease is Alzheimer disease.